Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.38% | -41.81% | -71.39% | -23.06% | -13.94% |
| Total Depreciation and Amortization | 48.59% | 49.08% | 54.42% | 56.40% | 49.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14,554.17% | 12,936.29% | 8,748.33% | -100.00% | -- |
| Change in Net Operating Assets | 81.04% | 60.97% | 62.62% | -1.25% | -72.61% |
| Cash from Operations | 57.44% | 39.71% | 28.97% | -9.33% | -42.73% |
| Capital Expenditure | 89.47% | 76.27% | -18.43% | -1,003.79% | -1,915.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.34% | 37.06% | 18.52% | 111.12% | 43.84% |
| Cash from Investing | 57.75% | 58.90% | 1.71% | -26.14% | -201.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 99.70% | 85.55% | 109.98% | 100.00% |
| Issuance of Common Stock | -60.70% | -46.09% | -12.04% | -69.44% | 195.19% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -480.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -46.90% | -22.64% | 42.55% | -58.54% | 161.02% |
| Foreign Exchange rate Adjustments | 182.03% | -2,049.64% | 141.07% | -1,077.63% | -321.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.47% | 56.32% | 85.38% | -400.52% | -19.37% |